This trial is testing a new drug combination for CLL patients, using Obinutuzumab and high-dose methylprednisone. It includes patients who are new to treatment and those who haven't responded to other treatments. The goal is to see if this combination can effectively target and destroy cancer cells while reducing inflammation. Obinutuzumab is a fully humanized antibody that targets specific cells and has been approved for use with other treatments in patients with previously untreated CLL.